These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 32903249)

  • 21. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin.
    Theoharides TC
    Biofactors; 2020 May; 46(3):306-308. PubMed ID: 32339387
    [No Abstract]   [Full Text] [Related]  

  • 22. Predictive factors of mortality in patients treated with tocilizumab for acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19).
    Lohse A; Klopfenstein T; Balblanc JC; Royer PY; Bossert M; Gendrin V; Charpentier A; Bozgan AM; Badie J; Bourgoin C; Contreras R; Mazurier I; Conrozier T; Zayet S
    Microbes Infect; 2020 Oct; 22(9):500-503. PubMed ID: 32574789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. COVID-19 Coagulopathy and Inflammation: The Knowns and Unknowns.
    Wanderer JP; Nathan N
    Anesth Analg; 2020 Nov; 131(5):1323. PubMed ID: 33079849
    [No Abstract]   [Full Text] [Related]  

  • 24. COVID-19 coagulopathy: an evolving story.
    The Lancet Haematology
    Lancet Haematol; 2020 Jun; 7(6):e425. PubMed ID: 32470428
    [No Abstract]   [Full Text] [Related]  

  • 25. D-Dimer serum levels as a biomarker associated for the lethality in patients with coronavirus disease 2019: a meta-analysis.
    Lima WG; Barra A; Brito JCM; Nizer WSC
    Blood Coagul Fibrinolysis; 2020 Jul; 31(5):335-338. PubMed ID: 32618589
    [No Abstract]   [Full Text] [Related]  

  • 26. Understanding the andromeda strain - The role of cytokine release, coagulopathy and antithrombin III in SARS-CoV2 critical illness.
    Mir N; D'Amico A; Dasher J; Tolwani A; Valentine V
    Blood Rev; 2021 Jan; 45():100731. PubMed ID: 32829961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Critical COVID-19 disease, homeostasis, and the "surprise" of effective glucocorticoid therapy.
    Chrousos GP; Meduri GU
    Clin Immunol; 2020 Oct; 219():108550. PubMed ID: 32745524
    [No Abstract]   [Full Text] [Related]  

  • 28. Lessons from dermatology about inflammatory responses in Covid-19.
    Criado PR; Pagliari C; Carneiro FRO; Quaresma JAS
    Rev Med Virol; 2020 Sep; 30(5):e2130. PubMed ID: 32656939
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treating COVID-19 with colchicine in community healthcare setting.
    Della-Torre E; Della-Torre F; Kusanovic M; Scotti R; Ramirez GA; Dagna L; Tresoldi M
    Clin Immunol; 2020 Aug; 217():108490. PubMed ID: 32492478
    [No Abstract]   [Full Text] [Related]  

  • 30. Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19.
    Laurence J; Mulvey JJ; Seshadri M; Racanelli A; Harp J; Schenck EJ; Zappetti D; Horn EM; Magro CM
    Clin Immunol; 2020 Oct; 219():108555. PubMed ID: 32771488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome.
    Chen LYC; Hoiland RL; Stukas S; Wellington CL; Sekhon MS
    Eur Respir J; 2020 Oct; 56(4):. PubMed ID: 32883678
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous N-acetylcysteine.
    Ibrahim H; Perl A; Smith D; Lewis T; Kon Z; Goldenberg R; Yarta K; Staniloae C; Williams M
    Clin Immunol; 2020 Oct; 219():108544. PubMed ID: 32707089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking.
    Magro G
    Virus Res; 2020 Sep; 286():198070. PubMed ID: 32569708
    [TBL] [Abstract][Full Text] [Related]  

  • 34. After 62 years of regulating immunity, dexamethasone meets COVID-19.
    Cain DW; Cidlowski JA
    Nat Rev Immunol; 2020 Oct; 20(10):587-588. PubMed ID: 32778829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interleukin-6 and severe COVID-19: a systematic review and meta-analysis.
    Mojtabavi H; Saghazadeh A; Rezaei N
    Eur Cytokine Netw; 2020 Jun; 31(2):44-49. PubMed ID: 32933891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Covid-19: The Rollercoaster of Fibrin(Ogen), D-Dimer, Von Willebrand Factor, P-Selectin and Their Interactions with Endothelial Cells, Platelets and Erythrocytes.
    Grobler C; Maphumulo SC; Grobbelaar LM; Bredenkamp JC; Laubscher GJ; Lourens PJ; Steenkamp J; Kell DB; Pretorius E
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708334
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extracorporeal Hemoadsorption: An Option for COVID-19-Associated Cytokine Storm Syndrome.
    Napp LC; Bauersachs J
    Shock; 2020 Nov; 54(5):700-701. PubMed ID: 32453251
    [No Abstract]   [Full Text] [Related]  

  • 38. Cellular immune responses to covid-19.
    Sewell HF; Agius RM; Stewart M; Kendrick D
    BMJ; 2020 Jul; 370():m3018. PubMed ID: 32737031
    [No Abstract]   [Full Text] [Related]  

  • 39. Thrombo-inflammatory features predicting mortality in patients with COVID-19: The FAD-85 score.
    Wang J; Zhang H; Qiao R; Ge Q; Zhang S; Zhao Z; Tian C; Ma Q; Shen N
    J Int Med Res; 2020 Sep; 48(9):300060520955037. PubMed ID: 32960106
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Coagulation abnormalities and thrombosis in patients with COVID-19.
    Levi M; Thachil J; Iba T; Levy JH
    Lancet Haematol; 2020 Jun; 7(6):e438-e440. PubMed ID: 32407672
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.